February 2, 2026 — Leads & Copy —
Ambry Genetics, a subsidiary of Tempus AI, Inc. (NASDAQ: TEM), has completed its one-millionth DNA/RNA test, marking a milestone in diagnostic accuracy. Ambry Genetics pioneered paired DNA/RNA testing for hereditary cancer a decade ago and remains a leading laboratory offering RNA testing insights across both hereditary cancer and exome testing.
The company first implemented RNA testing in 2016 as part of a research and validation pilot, commercially launching it in 2019 as +RNAinsight®. This advancement has improved hereditary cancer testing, enabling the identification of deep intronic pathogenic variants and resolving many uncertain variants. Analysis of data from over 450,000 patients tested with +RNAinsight® showed that 1 in 25 positive patients would have been missed without RNA data. The inclusion of RNA also leads to a 6% reduction in variants classified as uncertain. Overall, integrating RNA with DNA testing provides clinicians and their patients with clearer answers regarding hereditary cancer risk.
RNA data has also improved the equity of genetic test results. By leveraging functional evidence to address data gaps, RNA analysis has significantly impacted variant classification and reclassifications in non-White patients.
Ambry added RNA testing to its ExomeReveal® offering in 2024 to improve diagnostic yield in suspected rare disease cases.
According to Tom Schoenherr, CEO of Ambry Genetics, the company’s mission has been to bring clarity and actionable answers to patients and their families, while also advancing precision in genetic testing. He said that reaching one million RNA samples represents a million people who benefitted from potentially deeper insights into their genetics, helping to pinpoint risks sooner, make more informed decisions, and intervene confidently.
Huma Q. Rana, MD, MPH, Clinical Director of the Division of Cancer Genetics and Prevention at Dana-Farber Cancer Institute, and Assistant Professor of Medicine at Harvard Medical School, said that combining DNA and RNA provides an extra level of evidence to discover new variants and resolve ambiguity. She has seen this innovation clarify diagnoses and change management for her own patients.
Ambry Genetics translates scientific research into clinically actionable test results. Tempus provides AI-enabled precision medicine solutions to physicians. The goal is for each patient to benefit from the treatment of others who came before by providing physicians with tools that learn as the company gathers more data.
Source: Ambry Genetics
